Kidney Cancer Therapeutics Diagnostics Market Trends [2031]

Segments - Europe Kidney Cancer Therapeutics Diagnostics Market by Cancer Types (Clear cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma, and Others), Components (Drugs and Diagnostics), and Geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The Europe kidney cancer therapeutics diagnostics market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 5.7% during 2023–2031. The growth of the market is attributed to rising number of kidney cancer cases in the region.

Moreover, increasing research and development expenditure of the pharmaceutical companies is driving the market growth. One of the common symptoms of kidney cancer includes blood in urine, which may appear dark red, orange, or pink in color. As kidney cancer progresses, it may produce other symptoms, such as persistent pain or pressure below the ribs and intense fatigue.

Europe Kidney Cancer Therapeutics Diagnostics Market Outlook

Kidney cancer is the seventh most common cancer in the UK, which is responsible for around 12,600 new cases every year in the country, which equates to 34 cases every day and up to 30% of all people are diagnosed in the advanced stage of the disease. Over the last decade, kidney cancer incidence has risen by 47% and is projected to rise by 26% in the UK between 2014 and 2035.

Kidney cancer progression is diversified through four grade levels. Grade one kidney cancers have cells looking same as normal kidney cells, while cancer cells that look very different from normal cells are given a higher grade as they tend to grow faster than grade one kidney cells.

Market Trends, Drivers, Restraints, and Opportunities:

Increasing use of imaging techniques such as computerized tomography (CT) scans for diagnosing cancers is expected to contribute to the growth of the global Europe kidney cancer therapeutics diagnostics market.
Various options available for the treatments and presence of many drugs in pipeline are expected to augment the market growth.
Lack of awareness about the prevalence of kidney cancer can restraint the market growth.
The outbreak of COVID-19 has negatively impacted the Europe kidney cancer therapeutics diagnostics market. However, the market is anticipated to recover soon.
Increasing prevalence of kidney cancer is anticipated to increase the drug demand, propelling the growth of the market during the forecast period.

Scope of Europe Kidney Cancer Therapeutics Diagnostics Market Report

The report on the Europe kidney cancer therapeutics diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Kidney Cancer Therapeutics Diagnostics Market - Europe Industry Analysis, Growth, Share, Size, Trends, And Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Cancer Types (Clear cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma, Others), Components (Drugs and Diagnostics)
Geographical scope	Germany, United Kingdom, France, Italy, Spain, and Rest of Europe
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics

Europe kidney cancer therapeutics diagnostics Market Segment Insights:

Clear cell RCC segment to grow at a rapid pace

Based on cancer types, the market is divided into clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, and others. The clear cell RCC segment is anticipated to account for a key share and is anticipated to grow at a steady rate during the forecast period.

Clear cell RCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma (RCC) cases. Clear cell RCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.

Europe Kidney Cancer Therapeutics Diagnostics Market Cancer Types

Diagnostics segment to account a major market share

Based on components, the market is divided into drugs and diagnostics. The diagnostics segment is anticipated to account for a major share due to high prevalence of the disease, presence of diagnostic procedures and various treatment therapies, higher income levels in the region, rising preventive testing, and increasing number of healthcare and insurance services.

Europe Kidney Cancer Therapeutics Diagnostics Market Components

The United Kingdom to account a large market share

On the basis of geography, the market is segregated into Germany, United Kingdom, France, Italy, Spain, and Rest of Europe. The UK to account for a large market share during the forecast period. Rising prevalence of cancer and presence of reimbursement scenario are driving the growth of the market in the country. However, the market in Germany is expected to register substantial growth during the forecast period.

Segments

The global Europe kidney cancer therapeutics diagnostics has been segmented on the basis of

Cancer Types

Clear cell RCC
Papillary RCC
Chromophobe RCC
Urothelial Carcinoma
Others

Components

Drugs
Diagnostics

Key Players

Abbott Laboratories
Bayer AG
F. Hoffmann-La Roche Ltd
BRISTOL-MYERS SQUIBB COMPANY
Amgen Inc
Novartis AG
Pfizer Inc
Seattle Genetics

Competitive Landscape

The major players of the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics.

Companies are focusing on innovation, expansion, and acquisitions to expand their market share.

Europe Kidney Cancer Therapeutics Diagnostics Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Kidney Cancer Therapeutics Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Kidney Cancer Therapeutics Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Kidney Cancer Therapeutics Diagnostics Market - Supply Chain
  4.5. Global Kidney Cancer Therapeutics Diagnostics Market Forecast
     4.5.1. Kidney Cancer Therapeutics Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Kidney Cancer Therapeutics Diagnostics Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Kidney Cancer Therapeutics Diagnostics Market Absolute $ Opportunity
5. Global Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
6. North America Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
8. Europe Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Kidney Cancer Therapeutics Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Kidney Cancer Therapeutics Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Kidney Cancer Therapeutics Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Kidney Cancer Therapeutics Diagnostics Market: Market Share Analysis
  11.2. Kidney Cancer Therapeutics Diagnostics Distributors and Customers
  11.3. Kidney Cancer Therapeutics Diagnostics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbott Laboratories
     11.4.2. Bayer AG
     11.4.3. F. Hoffmann-La Roche Ltd
     11.4.4. BRISTOL-MYERS SQUIBB COMPANY
     11.4.5. Amgen Inc
     11.4.6. Novartis AG
     11.4.7. Pfizer Inc
     11.4.8. Seattle Genetics